CuriRx, Inc. was founded in 2012 with the goal of creating new standards of care in therapeutic areas with high unmet medical needs. We do this by partnering with our clients to provide innovative development solutions for pharmaceutics, biopharmaceutics, vaccines, generics, and biosimilars. Our unique approach allows for:
Customized development plans
Open discussion with strong consultative expertise
Guaranteed commitment and customer satisfaction
With passion, purpose, and partnerships, we transform scientific discoveries into advances in human healthcare.
Our people provide quality services and exceed customer expectations.
Long-term, strategic, mutually beneficial partnerships that result in consistent quality and continuous improvement.
Indu Javeri, PhD
Dr. Indu Javeri is an innovative and results-driven leader focused on achieving exceptional results in highly competitive environments that demand continuous improvement. She has over 30 years’ experience in driving product, improving processes, and providing quality service while building partnerships with key decision makers. Known for building and motivating successful teams, Dr. Javeri’s areas of expertise include CGMP regulatory compliance, formulation/lyophilization, process optimization, project management, research and development, supply chain management, and strategic planning.
Prior to founding CuriRx in 2012, Dr. Javeri co-founded Formatech, Inc., a contract services company specializing in formulation development and CGMP manufacture of clinical supplies, where she served as Chief Executive Officer for almost 20 years.
Dr. Javeri holds a PhD in Biochemistry from the University of Oklahoma.
Kaliappanadar "Nells" Nellaiappan, PhD
Dr. Kaliappanadar Nellaiappan has more than 25 years of experience in the development of new drugs and therapeutic agents. He has led various teams to develop more than 100 dosage formulations throughout his career and continues to head a product development group at CuriRx since 2012.
He has also been involved in developing novel drug delivery systems for both hydrophobic and hydrophilic molecules, including peptides, and polymer-based oral nanoparticles. He has seven approved patents, several patent applications pending, and more than 50 publications to his name.
Prior to joining CuriRx, Dr. Nellaiappan served as a senior scientist at Formatech, Inc., where he was involved in the strategic direction of formulation development and analytical method development for small molecules and biologics. Before Formatech, he worked at Mass Biologics, developing a vaccine for Shiga toxins.
Dr. Nellaiappan received his PhD from the University of Madras and received Royal Society bursary award from Oxford University. He did his post-doctoral work at UMass Boston and Boston University.
Bijay Misra, PhD
Dr. Bijay Misra brings to his role as Project Leader his expertise in formulation and analytical science and his more than 20 years of experience in pharmaceuticals and biotechnology. Over the course of his career, he has worked on the translation of drug candidates from discovery into development through studies of pharmaceutical materials science and drug delivery applications. Before joining CuriRx, Dr. Misra held positions of increasing responsibility in pharmaceutical research and development and cGMP manufacturing at Vertex, Alkermes, and Borregaard Synthesis.
Dr. Misra received his Ph.D. in physical-organic chemistry from the City University of New York and held a research fellow position in bioanalytical chemistry working on cancer research at the American Health Foundation in New York prior to joining the industry.